Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	112.25	113.34	118.9	102.1	116.18
Revenue Growth (YoY)	-0.96%	-4.68%	16.46%	-12.12%	-3.81%
Cost of Revenue	46.18	52.52	51.25	44.06	51.85
Gross Profit	66.07	60.82	67.65	58.04	64.32
Selling, General & Admin	46.89	49.53	48.95	43.43	46.02
Research & Development	11.76	12.33	10.8	8.69	10.72
Other Operating Expenses	5.53	5.89	5.84	5.71	7.21
Operating Expenses	64.18	67.75	65.59	57.82	63.95
Operating Income	1.89	-6.93	2.07	0.22	0.38
Interest Expense / Income	3.59	2.55	1.54	4.83	5.41
Other Expense / Income	0.86	-0.3	0.67	2.68	0.47
Pretax Income	-2.56	-9.18	-0.14	-7.29	-5.5
Income Tax	0.86	0.34	0.15	0.52	-0.82
Net Income	-3.42	-9.52	-0.29	-7.81	-4.69
Shares Outstanding (Basic)	42	41	40	39	38
Shares Outstanding (Diluted)	42	41	40	39	38
Shares Change	2.43%	2.65%	4.41%	2.18%	3.73%
EPS (Basic)	-0.08	-0.23	-0.01	-0.20	-0.12
EPS (Diluted)	-0.08	-0.23	-0.01	-0.20	-0.12
Free Cash Flow	11.72	-0.44	0.07	8.18	6.83
Free Cash Flow Per Share	0.28	-0.01	0.00	0.21	0.18
Gross Margin	58.86%	53.66%	56.90%	56.85%	55.37%
Operating Margin	1.69%	-6.12%	1.74%	0.22%	0.32%
Profit Margin	-3.04%	-8.40%	-0.24%	-7.65%	-4.03%
Free Cash Flow Margin	10.44%	-0.39%	0.06%	8.01%	5.88%
EBITDA	8.03	0.94	9.02	5.17	7.64
EBITDA Margin	7.16%	0.83%	7.59%	5.06%	6.58%
Depreciation & Amortization	7	7.58	7.62	7.63	7.73
EBIT	1.04	-6.63	1.4	-2.46	-0.09
EBIT Margin	0.92%	-5.85%	1.18%	-2.41%	-0.08%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).